Orexigen Therapeutics, Inc.
DelistedCIK 1382911fmd_0P4R2YN2D327Z01VMVM6FVNJVAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2017, 31 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 4 | 3 | 3 | 56 | 24 | 34 |
| Cost of revenue | – | – | – | – | – | – | – | 8 |
| Gross profit | – | – | – | – | – | – | – | 26 |
| Research and development | 47 | 28 | 13 | 74 | 57 | 57 | 41 | 38 |
| Selling, general and administrative | – | – | – | – | – | 29 | 44 | 119 |
| Total operating expenses | 66 | 53 | 32 | 94 | 81 | 86 | 85 | 83 |
| Operating income | (66) | (51) | (28) | (90) | (77) | (31) | (60) | (57) |
| Interest expense | 1 | 1 | 0 | 0 | 1 | 7 | 7 | 8 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other non-operating income (expense) | (1) | (1) | (0) | 0 | (0) | (7) | (7) | 33 |
| Income before taxes | – | – | – | – | (78) | (38) | (67) | (24) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 1 | 0 |
| Net income from continuing operations | – | – | – | – | (78) | (38) | (69) | (25) |
| Net income | (67) | (52) | (28) | (90) | (78) | (38) | (69) | (25) |